Thera-SAbDab

RANEVETMAB

>   Structural Summary
TherapeuticRanevetmab
TargetNGFB
Heavy ChainEVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS
Light ChainDIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatCanine Whole mAb
IsotypeG1
Highest Clinical Trial (June '19)Unknown
Estimated Status (June '19)Active
Recorded Developmental TechnologyPETization Technology
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedNexvet
Conditions Approvedna
Conditions ActiveOsterarthritis
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]